Lazard Asset Management
ESPR icon

Lazard Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Lazard Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-580,705
Closed -$1.59M – 2003
2026
Q1 		$1.59M Buy
580,705
+546,964
+1,621% +$1.73M ﹤0.01% 1012
2025
Q4 		$125K Buy
+33,741
New +$109K ﹤0.01% 1721
2025
Q2 		– Sell
-43,815
Closed -$63K – 2363
2025
Q1 		$63K Buy
43,815
+31,464
+255% +$58K ﹤0.01% 1942
2024
Q4 		$27K Hold
12,351
– – ﹤0.01% 2050
2024
Q3 		$20K Buy
12,351
+657
+6% +$1.33K ﹤0.01% 1999
2024
Q2 		$25K Buy
+11,694
New +$27.5K ﹤0.01% 2004
2023
Q1 		– Sell
-145,953
Closed -$909K – 2374
2022
Q4 		$909K Buy
145,953
+62,385
+75% +$446K ﹤0.01% 1014
2022
Q3 		$559K Buy
83,568
+51,176
+158% +$351K ﹤0.01% 1080
2022
Q2 		$206K Sell
32,392
-24,035
-43% -$136K ﹤0.01% 1276
2022
Q1 		$261K Buy
56,427
+20,136
+55% +$86.4K ﹤0.01% 1211
2021
Q4 		$181K Sell
36,291
-133,109
-79% -$1.07M ﹤0.01% 1297
2021
Q3 		$2.04M Buy
169,400
+142,400
+527% +$2.07M ﹤0.01% 911
2021
Q2 		$571K Buy
+27,000
New +$650K ﹤0.01% 1039
2018
Q2 		– Sell
-12,106
Closed -$875K – 1053
2018
Q1 		$875K Buy
+12,106
New +$889K ﹤0.01% 725
2015
Q3 		– Sell
-1,450
Closed -$118K – 1099
2015
Q2 		$118K Sell
1,450
-24,795
-94% -$2.43M ﹤0.01% 897
2015
Q1 		$2.43M Buy
26,245
+26,045
+13,023% +$1.68M 0.01% 617
2014
Q4 		$8K Buy
+200
New +$6.12K ﹤0.01% 1089

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Lazard Asset Management's ESPR Position: Q2 2026 in Review

Lazard Asset Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 580,705 shares — an estimated $1.59M sold.

Lazard Asset Management first reported a position in ESPR in Q4 2014 and held it in 17 quarters. The position peaked at $2.43M in Q1 2015. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Lazard Asset Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Lazard Asset Management sold 580,705 Esperion Therapeutics shares in Q2 2026, an estimated $1.59M.
  • Lazard Asset Management first reported a position in Esperion Therapeutics in Q4 2014 and held it in 17 quarters.
  • Lazard Asset Management's Esperion Therapeutics position peaked at $2.43M in Q1 2015.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.